Welcome & introduction
What’s new in obesity management guidelines?
Latest developments in approved pharmacological options – where is the evidence pointing?
From weight to health outcomes – what is proven?
Panel discussion
Moving beyond current pharmacological options
What is the role of amylin biology in weight management?
What do emerging clinical data focused on amylin analogues show?
From early-phase data to programme design – what is the development path for potential future therapies?
Panel discussion
Key takeaways & close